v3.26.1
General information (Details) - USD ($)
$ in Thousands
1 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
General Information About Financial Statements [Line Items]          
(Loss) / profit for the period   $ (65,791) $ 141,718    
Accumulated deficit $ (2,475,581) (2,475,581)   $ (2,409,790)  
Cash flows from (used in) operating activities   (80,214) 68,291    
Cash and cash equivalents 142,750 142,750 $ 151,452 $ 172,359 $ 51,428
Current assets less current liabilities 213,800 213,800      
June 2026 Financing Facility          
General Information About Financial Statements [Line Items]          
Borrowing facilities, maximum borrowing capacity 75,000 $ 75,000      
Ordinary Shares | June 2026 Offering          
General Information About Financial Statements [Line Items]          
Proceeds from issuing shares $ 164,600        
Aztiq Pharma Partners Sarl          
General Information About Financial Statements [Line Items]          
Proportion of ownership and voting power held by Alvotech   29.10%      
Alvogen          
General Information About Financial Statements [Line Items]          
Proportion of ownership and voting power held by Alvotech   28.20%      
Other Subsidiaries          
General Information About Financial Statements [Line Items]          
Proportion of ownership and voting power held by Alvotech   42.70%      
Maximum percentage of ownership interest held by each shareholder   0.024